Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN Podcasts

*Podcasts play in a pop-up window. Please make sure your pop-up blocker is off.

GEN’s editorial staff interviews life science academic and biotech industry leaders on important research, technology, and trends. These podcasts will keep you informed with all the important details you need.

Regulatory agencies are asking more questions about subvisible particles possibly present in some formulations and the potential of an immunogenic effect. Companies developing biotech drugs must gain a clear understanding of this issue if they hope to successfully compete in the pharmaceutical marketplace.

During this podcast Dr. Atkinson defines subivisible particles and talks about the top five issues that drug manufacturers absolutely need to know about such particles. He reviews the specific requests the FDA has made to the pharma industry for dealing with subvisible particles and discusses those analytical tools that are used most often to measure protein aggregates and subvisible/visible particles.

E. Morrey Atkinson, Ph.D. serves as  vp of R&D and CSO at Cook Pharmica. Dr. Atkinson is responsible for guiding the scientific direction of Cook Pharmica, relying on his past experience with process development of gene therapies, vaccines, recombinant proteins, and mAbs.

Dr. Atkinson has almost two decades of experience in biologic development and has held various leadership positions in biotechnology manufacturing and development. Most recently, he was head of biotechnology manufacturing sciences and technology for Eli Lilly in Kinsale, Ireland.

Dr. Atkinson, who grew up in Indiana and Florida, graduated from Indiana University with a B.S. in biology and received his doctorate in biological sciences from Stanford University.

  • Add a comment

  • Click here to Login/Register for free. You will be taken back to your selected item after Login/Registration.

Related content

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »